Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jul 23

PMID 27447181

Citations 24

Authors

Tommaso Azzarito

Luana Lugini

Enrico Pierluigi Spugnini

Rossella Canese

Alessio Gugliotta

Stefano Fidanza

Stefano Fais

Affiliations

Soon will be listed here.

Abstract

Tumor extracellular acidity is a hallmark of malignant cancers. Thus, in this study we evaluated the effects of the oral administration of a commercially available water alkalizer (Basenpulver®) (BP) on tumor growth in a syngenic melanoma mouse model. The alkalizer was administered daily by oral gavage starting one week after tumor implantation in CB57/BL mice. Tumors were calipered and their acidity measured by in vivo MRI guided 31P MRS. Furthermore, urine pH was monitored for potential metabolic alkalosis. BP administration significantly reduced melanoma growth in mice; the optimal dose in terms of tolerability and efficacy was 8 g/l (p< 0.05). The in vivo results were supported by in vitro experiments, wherein BP-treated human and murine melanoma cell cultures exhibited a dose-dependent inhibition of tumor cell growth. This investigation provides the first proof of concept that systemic buffering can improve tumor control by itself and that this approach may represent a new strategy in prevention and/or treatment of cancers.

Citing Articles

How Does Cancer Occur? How Should It Be Treated? Treatment from the Perspective of Alkalization Therapy Based on Science-Based Medicine.

Hamaguchi R, Isowa M, Narui R, Morikawa H, Okamoto T, Wada H Biomedicines. 2024; 12(10).

PMID: 39457509 PMC: 11504456. DOI: 10.3390/biomedicines12102197.

Exploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy.

Isowa M, Hamaguchi R, Narui R, Morikawa H, Okamoto T, Wada H Pharmaceutics. 2024; 16(6).

PMID: 38931908 PMC: 11207558. DOI: 10.3390/pharmaceutics16060787.

Potential of Alkalization Therapy for the Management of Metastatic Pancreatic Cancer: A Retrospective Study.

Isowa M, Hamaguchi R, Narui R, Morikawa H, Okamoto T, Wada H Cancers (Basel). 2024; 16(1).

PMID: 38201489 PMC: 10777900. DOI: 10.3390/cancers16010061.

Innate lymphoid cells and tumor-derived lactic acid: novel contenders in an enduring game.

Marciniak M, Wagner M Front Immunol. 2023; 14:1236301.

PMID: 37868977 PMC: 10585168. DOI: 10.3389/fimmu.2023.1236301.

Ionized alkaline water reduces injury in BALB/c mice infected with Leishmania amazonensis.

Retamiro K, Nunes K, Zani A, Zani C, Beltran L, de Oliveira Silva S PLoS One. 2023; 18(7):e0280695.

PMID: 37410769 PMC: 10325109. DOI: 10.1371/journal.pone.0280695.

References

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell H, Ibrahim-Hashim A . Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73(5):1524-35. PMC: 3594450. DOI: 10.1158/0008-5472.CAN-12-2796. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Fais S . Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med. 2010; 267(5):515-25. DOI: 10.1111/j.1365-2796.2010.02225.x. View

Spugnini E, Baldi A, Buglioni S, Carocci F, de Bazzichini G, Betti G . Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med. 2011; 9:221. PMC: 3264547. DOI: 10.1186/1479-5876-9-221. View

De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino M . Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007; 67(11):5408-17. DOI: 10.1158/0008-5472.CAN-06-4095. View

Parks S, Chiche J, Pouyssegur J . Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013; 13(9):611-23. DOI: 10.1038/nrc3579. View

Wang B, Zhang J, Wang J, Sun S, Wang Z, Wang L . Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015; 34:85. PMC: 4546346. DOI: 10.1186/s13046-015-0194-x. View

Spugnini E, Buglioni S, Carocci F, Francesco M, Vincenzi B, Fanciulli M . High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med. 2014; 12:225. PMC: 4145230. DOI: 10.1186/s12967-014-0225-y. View

Cairns R, Harris I, Mak T . Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2):85-95. DOI: 10.1038/nrc2981. View

10.

Ibrahim-Hashim A, Cornnell H, Abrahams D, Lloyd M, Bui M, Gillies R . Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol. 2012; 188(2):624-31. PMC: 3694604. DOI: 10.1016/j.juro.2012.03.113. View

11.

Suckling R, Swift P . The health impacts of dietary sodium and a low-salt diet. Clin Med (Lond). 2015; 15(6):585-8. PMC: 4953267. DOI: 10.7861/clinmedicine.15-6-585. View

12.

Jackson S, Coleman King S, Zhao L, Cogswell M . Prevalence of Excess Sodium Intake in the United States - NHANES, 2009-2012. MMWR Morb Mortal Wkly Rep. 2016; 64(52):1393-7. DOI: 10.15585/mmwr.mm6452a1. View

13.

Olbe L, Carlsson E, Lindberg P . A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003; 2(2):132-9. DOI: 10.1038/nrd1010. View

14.

Ota T, Uchida S . [Kidney diseases and metabolic disorders--Basics and applications required for general physicians. Topics: I. Disorders of water balance and sodium metabolism]. Nihon Naika Gakkai Zasshi. 2015; 104(5):906-16. DOI: 10.2169/naika.104.906. View

15.

Taylor S, Spugnini E, Assaraf Y, Azzarito T, Rauch C, Fais S . Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015; 23:69-78. DOI: 10.1016/j.drup.2015.08.004. View

16.

Tomey M, Winston J . Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health. 2014; 80(1):69-76. DOI: 10.1016/j.aogh.2013.12.007. View

17.

De Milito A, Marino M, Fais S . A rationale for the use of proton pump inhibitors as antineoplastic agents. Curr Pharm Des. 2012; 18(10):1395-406. DOI: 10.2174/138161212799504911. View

18.

Tremoleda J, Kerton A, Gsell W . Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare. EJNMMI Res. 2012; 2(1):44. PMC: 3467189. DOI: 10.1186/2191-219X-2-44. View

19.

Silva A, Yunes J, Gillies R, Gatenby R . The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009; 69(6):2677-84. PMC: 3718046. DOI: 10.1158/0008-5472.CAN-08-2394. View

20.

Marino M, Fais S, Djavaheri-Mergny M, Villa A, Meschini S, Lozupone F . Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2011; 1:e87. PMC: 3035900. DOI: 10.1038/cddis.2010.67. View